News Combination between Novozymes and Chr. Hansen approved by the Novozymes shareholders Staff March 30, 2023 Please read the announcement in PDF Attachment 2023_50_Combination_between_Novozymes_and_Chr._Hansen_approved_by_the_Novozymes_shareholders Post Navigation Previous GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal InfectionNext Combination between Novozymes and Chr. Hansen approved by Novozymes’ shareholders More Stories News Patient Care Casect Launches AI-Enhanced Case Log Platform for Surgeons Staff December 25, 2024 News CorVel Announces Effectiveness of Three-For-One Forward Stock Split Staff December 25, 2024 Cancer Clinical Trial DNA Melanoma News Pharmaceutical Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca Staff December 25, 2024